Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine + fludarabine + cyclophosphamide conditioning before allogeneic stem cell transplantation for refractory follicular lymphoma
jRCTs031180072Phase 1Completed
- Sponsor
- ICMR-Regional Medical Research Centre
- Start
- Mar 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bendamustine, fludarabine and cyclophosphamide in follicular lymphoma (FL) and low-grade B-cell lymphoma, sponsored by ICMR-Regional Medical Research Centre. Primary endpoint: Incidence of dose-limiting toxicity. Started Mar 2014; status: completed.
02
Drugs
bendamustinefludarabinecyclophosphamide
03
Conditions
follicular lymphoma (FL)low-grade B-cell lymphoma
Beyond the preview
Go deeper on jRCTs031180072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180072.